Coherus Oncology (CHRS) Return on Equity (2014 - 2026)

Coherus Oncology has disclosed Return on Equity across 13 years of filings, most recently posting 0.05% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.05%, up 6.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.05% (up 6.0% YoY), and the FY2025 annual result was 0.1%, down 8.0% from the prior year.
• Return on Equity came in at 0.05% for Q1 2026 at Coherus Oncology, up from 0.05% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.05% in Q1 2026 to a low of 0.11% in Q2 2025.
• The 5-year median for Return on Equity is 0.01% (2022), against an average of 0.0%.
• Across the five-year window, Return on Equity declined 10 bps in 2022 and advanced 13 bps in 2023, its largest moves.
• Coherus Oncology's Return on Equity stood at 0.02% in 2022, then slumped by 42 bps to 0.01% in 2023, then sank by 253 bps to 0.02% in 2024, then soared by 312 bps to 0.05% in 2025, then advanced by 9 bps to 0.05% in 2026.
• The last three Return on Equity figures came in at 0.05% (Q1 2026), 0.05% (Q4 2025), and 0.03% (Q3 2025), per Business Quant data.